Analysis of HIV-1 latent reservoir and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117

Abstract

SummaryIn the setting of a clinical trial evaluating the anti-HIV-1 antibody 3BNC117, Cohen et al. demonstrate that rebound viruses that emerge following interruption of antiretroviral therapy are distinct from circulating latent viruses. However, rebound viruses often appear to be recombinants between isolated latent viruses. By incorporating the possibility of recombination, 63% of the rebound viruses could have derived from the observed latent reservoir. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating reservoir, but instead appear to represent recombinants. AbstractAll rights reserved. No reuse allowed without permission.(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

“…Consistent with previous results, 64% and 71% of the outgrowth viruses were sensitive to 3BNC117 and 10-1074, respectively, and 48% were sensitive to both (IC 50 ≤ 2μg/ml, Extended Data Fig. 1a and Supplementary Table 1)8,9,20.…”

“…10). Similar to previous reports, 63% of all viruses obtained by Q 2 VOA belonged to expanded clones20,24–26(Extended Data Fig. 10a, b).…”

“…7). The difference could be accounted for by distinct requirements for HIV-1 reactivation in vitro and in vivo , compartmentalization of reservoir viruses, HIV-1 mutation during the course of the trial, and/or by viral recombination in some individuals20,21 (Extended Data Fig. 8).…”

Espektro zabaleko antigorputzen rola GIBaren aurkako terapian eta prebentzioan

“…GIBarekin infektatutako banakoen tratamenduaren emaitzak aztertzean, hauek populazio heterogeneo bat osatzen dutela kontuan hartu behar da. Batetik, ART hartzen ari diren banakoak izan daitezke [26][27][28][29] edota tratamendua gelditu berri dutenak [26,27,29] eta azkenik, infekzio kronikoa duten eta ART hartzen ari ez direnak [28][29][30][31][32].…”

Development of a lectin-Fc fusion protein with antiviral and anti-cancer activity.

“…In order for this to be effective, the bNAb must be able to recognize infected cells and effectively elicit ADCC. To date, few descriptions of antibodies that are capable of this have been published [65,[85][86][87]. As demonstrated in this work, AvFc can effectively recognize SIV-infected MLN cells isolated from rhesus macaques (Figure 8), opening up the possibility that any SIV-infected cells can be targeted and possibly eliminated through ADCC in vivo in combination with an LRA.…”